Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report)’s share price rose 9.5% during trading on Monday . The company traded as high as $9.47 and last traded at $9.5450. Approximately 434,167 shares traded hands during mid-day trading, a decline of 58% from the average session volume of 1,029,245 shares. The stock had previously closed at $8.72.
Analyst Ratings Changes
Several research firms have recently weighed in on IMMX. Bank of America assumed coverage on Immix Biopharma in a research report on Thursday. They set a “buy” rating and a $27.00 price objective for the company. Wall Street Zen cut Immix Biopharma from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Mizuho upped their price target on Immix Biopharma from $14.00 to $15.00 and gave the stock an “outperform” rating in a research report on Monday, March 30th. Morgan Stanley assumed coverage on Immix Biopharma in a research report on Wednesday, March 25th. They set an “overweight” rating and a $20.00 price target for the company. Finally, HC Wainwright raised their price target on shares of Immix Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, May 22nd. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.67.
Get Our Latest Stock Analysis on Immix Biopharma
Immix Biopharma Stock Up 7.3%
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. Sell-side analysts predict that Immix Biopharma, Inc. will post -0.69 earnings per share for the current fiscal year.
Institutional Trading of Immix Biopharma
A number of large investors have recently added to or reduced their stakes in IMMX. Janus Henderson Group PLC grew its position in shares of Immix Biopharma by 22.5% in the 1st quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company’s stock valued at $43,698,000 after acquiring an additional 880,434 shares during the period. Eventide Asset Management LLC bought a new stake in shares of Immix Biopharma in the 4th quarter valued at about $13,331,000. Marshall Wace LLP lifted its stake in Immix Biopharma by 3,495.4% in the 4th quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock valued at $10,349,000 after purchasing an additional 1,923,708 shares during the last quarter. Millennium Management LLC acquired a new stake in Immix Biopharma in the 4th quarter valued at about $8,681,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in Immix Biopharma in the 4th quarter valued at about $7,845,000. Institutional investors and hedge funds own 11.26% of the company’s stock.
About Immix Biopharma
Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.
The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.
Read More
- Five stocks we like better than Immix Biopharma
- Buy CrowdStrike Before the Stock Split? Here’s the Case
- Investors Are Buying Into Sweetgreen Again—Should They?
- Burlington Is Winning Over Shoppers But Investors Need Patience
- USA Today’s Digital Revival Is Gaining Steam, But With Plenty of Risk
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
